# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate.
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issu...
Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under na...
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as...
ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $...
Wedbush analyst Andreas Argyrides reiterates ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and maintains $19 price tar...
Significant unmet need with 80-90% of patients with current epinephrine Rx not using as directed, and only ~15% of diagnosed se...
Leerink Partners analyst Roanna Ruiz upgrades ARS Pharmaceuticals (NASDAQ:SPRY) from Market Perform to Outperform and raises...
ARS Pharmaceuticals reports Phase 2 study results for neffy (epinephrine nasal spray) treating chronic spontaneous urticaria. S...